RIO Trial
@riotrial.bsky.social
Hello, RIO Trial is also now on Bluesky!
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
The RIO study is looking at whether a new type of treatment (bNAbs) can keep HIV viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
https://riotrial.org/
Reposted by RIO Trial
As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025
March 12, 2025 at 7:58 PM
As RIO and other groups have shown, bNAbs may be most promising as an immunotherapeutic intervention to enhance immun rasponsew, rather than as ART treatment. #CROI2025
You can find out more about the latest study developments at riotrial.org
RIO HIV Trial - Viral suppression off ART using dual bNAb therapy
RIO is looking at whether a new type of treatment, called bNAbs can keep viral load undetectable without antiretroviral treatment (ART)
riotrial.org
March 11, 2025 at 7:21 PM
You can find out more about the latest study developments at riotrial.org
The study is still ongoing, with follow-up of the participants still part of the protocol continuing until 2027. Final results of all remaining protocol defined endpoints are anticipated towards the end of 2027, while a new arm of the study will also be opening soon to new participants.
March 11, 2025 at 7:21 PM
The study is still ongoing, with follow-up of the participants still part of the protocol continuing until 2027. Final results of all remaining protocol defined endpoints are anticipated towards the end of 2027, while a new arm of the study will also be opening soon to new participants.
While these results are still preliminary, they suggest bNAb therapies could offer a new path to managing HIV and possibly lead to a cure.
March 11, 2025 at 7:21 PM
While these results are still preliminary, they suggest bNAb therapies could offer a new path to managing HIV and possibly lead to a cure.
This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.
March 11, 2025 at 7:21 PM
This study is the first to show sustained viral control using these immune-based therapies. The bNAbs not only targeted HIV directly but also stimulated the immune system, with some participants achieving undetectable levels of HIV in their reservoirs.
The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.
March 11, 2025 at 7:21 PM
The results showed that 75% of participants who received bNAbs were able to control the virus for 20 weeks, compared to those who received a placebo over the same timeframe.
Reposted by RIO Trial
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
March 10, 2025 at 6:48 PM
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.